Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Yondelis opvejer risiciene ved behandling af fremskredent bløddelssarkom, når antracykliner og ifosfamid ikke længere virker eller ikke kan anvendes til patienten.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Yondelis’ s benefits are greater than its risks for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.